Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Asset Writedowns and Impairment (2016 - 2025)

Historic Asset Writedowns and Impairment for Guided Therapeutics (GTHP) over the last 5 years, with Q3 2025 value amounting to $2000.0.

  • Guided Therapeutics' Asset Writedowns and Impairment changed N/A to $2000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1000.0, marking a year-over-year increase of 20000.0%. This contributed to the annual value of $23000.0 for FY2022, which is N/A changed from last year.
  • According to the latest figures from Q3 2025, Guided Therapeutics' Asset Writedowns and Impairment is $2000.0.
  • Over the past 5 years, Guided Therapeutics' Asset Writedowns and Impairment peaked at $2000.0 during Q3 2025, and registered a low of $2000.0 during Q3 2025.